Table 2

Baseline demographic data for all treatment groups: European data

Treatment


Characteristics
 2 mg/kg (n = 53)
 4 mg/kg (n = 54)
 8 mg/kg (n = 52)
 2 mg/kg + MTX (n = 52)
 4 mg/kg + MTX (n = 49)
 8 mg/kg + MTX (n = 50)
 MTX (n = 49)
 All groups (n = 359)
Age (years)
 52.2
 49.3
 50.1
 49.2
 50.2
 50.1
 50.9
 50.3
Sex (male/female)
 9/44
 13/41
 14/38
 7/45
 12/37
 11/39
 11/38
 77/282
Duration of RA (years)
 9.19
 9.79
 9.21
 9.33
 7.82
 10.62
 11.24
 -
TJC (28)
 15
 15
 15
 15
 13
 15
 16
 15
SJC (28)
 11
 11
 12
 11
 11
 11
 12
 11
ESR (mm/hour)
 39a
 41
 39b
 45c
 40
 39d
 43
 41
CRP (mg/l)
 26a
 19
 22b
 28c
 31
 24d
 32
 27
DAS28
 6.48a
 6.55
 6.43b
 6.58c
 6.34
 6.47d
 6.75
RF positive (n)
 44
 39
 43
 46
 38
 40
 47

an = 52; bn = 51; cn = 50; dn = 49. CRP, C-reactive protein; DAS28, Disease Activity Score; ESR, erythrocyte sedimentation rate; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; SJC, swollen joint count; TJC, total joint count. Reproduced, with permission, from [13].

Smolen and Maini Arthritis Research & Therapy 2006 8(Suppl 2):S5   doi:10.1186/ar1969